Announced strategic research collaboration with Chugai for two undisclosed molecules – – Presented preclinical data ...

NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque ...

Significant regulatory advances for lead candidate EB613 streamline Phase 3 clinical development and reduce regulatory hurdles. These 10 stocks could mint the next wave of millionaires › Entera Bio ...

Enrollment in the global Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) in ATTR with cardiomyopathy (ATTR-CM) continues to trac ...

Stock dividend issued to IMUNON shareholders reflects confidence in clinical programs, long-term growth strategy and dedication to rewarding sharehol ...

THE Philippine Council for Health Research and Development (PCHRD) is seeking stronger alignment between health research and policymaking as it hosts the 18th Philippine National Health Research ...

Net loss (GAAP) increased by $5,600,000 to $16,600,000 for the fiscal third quarter ended June 30, 2025, reflecting a ...

Q2 2025 Earnings Call Transcript August 6, 2025 Fortrea Holdings Inc. beats earnings expectations. Reported EPS is $0.19, ...

Detailed price information for 4D Molecular Therapeutics Inc (FDMT-Q) from The Globe and Mail including charting and trades.

Financial Guidance: Celldex believes that the cash, cash equivalents and marketable securities at June 30, 2025 are sufficient to meet estimated working capital requirements and fund current planned ...

Q2 2025 Earnings Call Transcript August 6, 2025 Operator: Good day, and thank you for standing by. Welcome to the Q2 2025 ...

Detailed price information for Eyepoint Pharmaceuticals Inc (EYPT-Q) from The Globe and Mail including charting and trades.